Compare FIX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIX | REGN |
|---|---|---|
| Founded | 1917 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.9B | 73.2B |
| IPO Year | 1997 | 1995 |
| Metric | FIX | REGN |
|---|---|---|
| Price | $1,942.43 | $604.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 25 |
| Target Price | ★ $1,798.60 | $830.16 |
| AVG Volume (30 Days) | 351.2K | ★ 989.5K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | 0.19% | ★ 0.55% |
| EPS Growth | ★ 97.81 | 8.19 |
| EPS | ★ 10.51 | 6.75 |
| Revenue | ★ $9,101,641,000.00 | $5,872,227,000.00 |
| Revenue This Year | $21.43 | $12.45 |
| Revenue Next Year | $13.14 | $10.13 |
| P/E Ratio | $182.73 | ★ $91.17 |
| Revenue Growth | ★ 29.52 | 20.82 |
| 52 Week Low | $489.98 | $506.38 |
| 52 Week High | $2,073.99 | $821.11 |
| Indicator | FIX | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 36.29 |
| Support Level | $1,736.87 | $591.52 |
| Resistance Level | $2,023.33 | $618.01 |
| Average True Range (ATR) | 99.20 | 15.46 |
| MACD | 4.48 | 3.14 |
| Stochastic Oscillator | 80.12 | 29.37 |
Comfort Systems USA Inc provides comprehensive mechanical contracting services, including heating, ventilation, & air conditioning, or HVAC; plumbing; piping & controls; construction; and other electrical components. Projects are mainly for commercial, industrial, & institutional buildings, & tend to be geared toward HVAC. Revenue is roughly split between installation services for newly constructed facilities & maintenance services for existing buildings. The company installs & repairs products and systems throughout the United States. It operates in two segments, Mechanical services & Electrical services, the majority is from the Mechanical services segment.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.